Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • New pharma policy to...

    New pharma policy to restrict power of NPPA to fix prices

    Written by Ruby Khatun Khatun Published On 2017-08-18T17:00:01+05:30  |  Updated On 18 Aug 2017 5:00 PM IST
    New pharma policy to restrict power of NPPA to fix prices

    New Delhi: The government has come up with a new draft pharmaceutical policy for prescribing the level of trade margins to bring down the prices of drugs. The draft also states that the drug pricing regulators will have the power to fix the prices of essential medicines only.


    Currently, the National Pharmaceutical Pricing Authority (NPPA) functions as an autonomous body that regulates prices of medicines under the National List of Essential Medicines as well as other medicines that are not on the list. However, it has now been proposed to limit the powers of this apex regulator to fixing prices of essential drugs only.


    According to the latest draft pharma policy prepared by Department of Pharmaceuticals (DoP), NPPA can cap prices of only those drugs included in the National List of Essential Medicines (NLEM). The NPPA should lay down and enforce price ceilings of “selected medicines” and ensure that “adequate quantities” of the drugs are available.


    While other recommendations have been made by the policy to strengthen the regulatory body, at the same time NPPA may lose the absolute power to fix drug prices, if this policy comes into effect


    “National List of Essential Medicines will remain the basis of the medicines to be brought under price regulation… the Department of Pharmaceuticals will prepare the list of medicines for price regulation and transmit them to the NPPA for fixing the price ceilings,” ET quotes the latest draft of the pharmaceuticals policy as stating.


    The draft policy talks about making the voluntary code for marketing a mandatory requirement for companies operating in India. “Doctors are lured to recommend a particular brand through all expenses paid trips often disguised and called ‘educational conventions’ and such other incentives. While The Drugs & Magic Act prohibits any advertisement of a drug, such ‘educational’ conferences are used to circumvent and play the trick. These add to the overhead cost of the drugs," quotes Business Standard


    The draft also states that the government intends to push the sale of medicines using the salt name instead of the brand for generic drugs.


    Fixed-dose combination drugs will be allowed to put a brand name, however, rest of the drugs would have generic names only. Proposal for e-prescriptions is also part of the draft so that doctors prescribe generic names without any hassle.

    Department of PharmaceuticalsDOPdrugsDrugs and Magic Actessential medicinesfix pricesFixed Dose CombinationNational List of Essential MedicinesNational Pharmaceutical Pricing AuthorityNew pharma policyNLEMNPPApowerrestricttrade margins
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok